Processing and Product Quality Issues Keith Wonnacott Ph.D. Office of Cellular, Tissue, and Gene Therapies E BC R Moving from Investigational to Licensed

Processing and Product Quality Issues

Processing and Product Quality Issues

Keith Wonnacott Ph.D.

Office of Cellular, Tissue, and Gene Therapies

EBCR

Moving from Investigational to Licensed Islet Products

Moving from Investigational to Licensed Islet Products

EBCR

OverviewOverview

• FDA regulation of islets

• Issues related to islet product quality– Source materials– Manufacturing process– Product testing

• Issues related to islet comparability

EBCR

OverviewOverview




EBCR

FDA Regulation of IsletsFDA Regulation of Islets

September 8, 2000

Dear Colleague: The purpose of this letter is to inform or remind you of how the Food and Drug Administration (FDA) regulates allogeneic pancreatic islets for transplantation. These cellular therapies are regulated as biological products subject to licensing under Section 351 of the Public Health Service Act (PHS Act). 42 USC 262. They also meet the definition of "drug" in the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 USC 321(g), and are thus subject to certain requirements of the FD&C Act. An Investigational New Drug (IND) application should be submitted for review by FDA and be in effect prior to the initiation of clinical studies in humans of allogeneic pancreatic islets for transplantation.……

EBCR

Islets as an FDA Licensed Product

Islets as an FDA Licensed Product

• What would be licensed?– The final islet cellular product – The manufacturing process is not licensed,

however, a licensed product is dependent upon a specific manufacturing process

• In the absence of extensive product characterization, the manufacturing process helps to define the final product

EBCR

Biologics License Application (BLA)Biologics License Application (BLA)

21 CFR 601.2:

The manufacturer…shall submit data derived from nonclinical laboratory and clinical studies which demonstrate that the manufactured product meets prescribed requirements of safety, purity, and potency

CGMPGLP

Preclinical Phase 1 Phase 2 Phase 3 BLA

Product Quality

Standards

Product Characterization

Applying Quality Standards During Product Development

Applying Quality Standards During Product Development

Product QualitySafe, Pure, Potent

Buildings and

Facilities

Packing and Labeling

Control of Components

Manufacturing Controls

Laboratory Controls/

Product Testing

Records and Reports

Holding and

Distribution

Organization and

Personnel

EBCR

Quality and ControlQuality and Control


Control of Source Material Manufacturing

Controls

Product Testing

EBCR

OverviewOverview





Control of Source Material

CMC Question #1CMC Question #1Quality control of the source material (cadaveric organs)

EBCR

Source Material Control:Islet source material is variable

Source Material Control:Islet source material is variable

Because the source material for islets are cadaveric organs, it cannot be controlled in a traditional way because:

• Each organ is unique– Organ size, donor age, extent of fibrosis and

autolysis

• Organ procurement procedures may vary– Ischemia time, transport media, organ core

temperature

EBCR

Source Material Control:Ensuring quality source materialSource Material Control:Ensuring quality source material

A key component for ensuring control of a validated islet manufacturing process is the use of pre-defined acceptance criteria for the source material (donor organ).

Acceptance criteria should ensure that: • suitable donor organs (organs with maximal

potential for yielding adequate numbers of islets) are used for islet manufacturing

• unsuitable organs are excluded from further manufacture

EBCR

Source Material Control:Donor organ acceptance criteriaSource Material Control:Donor organ acceptance criteria

Acceptance criteria may include:

• Donor suitability determination

• Organ characteristics

• Harvesting conditions

• Transport conditions

EBCR

CMC Question # 1CMC Question # 1

Please discuss the data needed for developing pre-

defined acceptance criteria for source organs


Manufacturing Controls CMC Question #2CMC Question #2

Quality control of the manufacturing process

EBCR

Manufacturing Control:Expectations

Manufacturing Control:Expectations

• In order to produce a product that is consistent in safety, purity, and potency the manufacturing process should be standardized and validated

• In-process testing should confirm the consistency of the process

• Licensed products, and the process by which they are made, are not experimental and have been shown to be safe and effective– Experimental procedures result in experimental

products

EBCR

Manufacturing Control:Manufacturing changes

Manufacturing Control:Manufacturing changes

• Manufacturing changes can impact product safety, identity, purity, potency, consistency and stability in unforeseen ways.

• Therefore, the product used in pivotal trials should be representative of the product that is intended to be licensed.

EBCR

Manufacturing Control:Current status


• Investigators frequently “customize” an islet isolation procedure, based on a given donor organ’s characteristics, to optimize the yield of islets

• There are many variations in isolation methods; both within centers and across centers

EBCR



• Examples of manufacturing variations include:– Digestion time and temperature – Use of additives such as DNase and

protease inhibitors– Issues with the critical digestive enzyme

(Liberase)– Culturing islets prior to transplantation

EBCR

Manufacturing Control:Finding a balance

Manufacturing Control:Finding a balance

• FDA agrees that some flexibility in the manufacturing process is acceptable, if conducted using predefined criteria or algorithms within a validated manufacturing protocol

• These predefined criteria would establish conditions that would allow for processing variations based on the characteristics of each donor organ

EBCR

CMC Question #2CMC Question #2

Is it reasonable to expect that criteria or algorithms can be developed,

based on data collected during IND studies, to predetermine under what

conditions the use of a specific reagent, reagent concentration, or processing method is appropriate?


Product Testing CMC Question #3CMC Question #3

Quality control of the final product

EBCR

Product Testing:Expectations

Product Testing:Expectations

• Release testing should be performed on a sample of the final product

• Some test methods are prescribed by regulation, and some are proposed by the BLA applicant

• Each test result should contribute meaningful information about the safety, purity, and potency of the product

EBCR

Part 610 Test Test Method Test Timing Specification

Sterility Specified Final Product Negative

Purity (pyrogenicity)

Specified Final Product Pass

Identity Not Specified* Final Product Product Specific*

Potency Not specified* Final Product Product Specific*

Product Testing:Biological Product Standards


EBCR

Part 610 Test Test Method Test Timing Specification

Sterility Specified Final Product Negative

Purity (pyrogenicity)

Specified Final Product Pass

Identity Not Specified* Final Product Product Specific*

Potency Not specified* Final Product Product Specific*



EBCR

Product Testing:Potency

Product Testing:Potency

21 CFR 600.3 (s)

The word potency is interpreted to mean the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner intended, to effect a given result.

EBCR

Product Testing:Challenges for potencyProduct Testing:Challenges for potency

• Results should be available before the product is released

• Results should show the ability to effect a given result– Potency will ideally correlate with the

biological activity that provides the intended therapeutic effect of the product in vivo

EBCR

Product Testing:Current status of potency testing

Product Testing:Current status of potency testing

• Examples of current potency assays:– glucose stimulated insulin release – or injection of islets under the kidney

capsule of diabetic mice to restore proper control of blood sugar

* However, these results are not available prior to the release of the product

EBCR

Product Testing:Considerations

Product Testing:Considerations

• An acceptable lot release potency assay is required for BLA

• If bioassays aren’t feasible for lot release, the applicant may provide rationale for other approaches to ensure product potency– Ex: viability + other characteristics

(dithizone staining)

EBCR


Please discuss any assay or assays that are currently, or could be,

performed on the final islet product before patient administration, which may be predictive of the ability of the

islets to perform as expected after patient administration.

EBCR

OverviewOverview




EBCR

Product ComparabilityProduct Comparability

• Comparability is demonstrating that critical product characteristics including safety, purity, and potency have not changed even when the manufacturing process has changed

• Products manufactured with different processes are considered to be different products until comparability is demonstrated

EBCR

Product Comparability:Test methods

Product Comparability:Test methods

Comparability testing may include:

• Analytical assays

• Bioassays

• Preclinical studies

• Clinical studies

EBCR

Product Comparability:Why does it matter?

Product Comparability:Why does it matter?

• In general, each license is for one product produced by one manufacturing process

• It is unclear how differences in methods to prepare allogeneic islets by various groups impact the characteristics of the final allogeneic islet product

• Data from different manufacturing facilities, or the same facility using different processes, cannot be used to support the same BLA unless comparability is demonstrated

EBCR


What should be the key criteria (measures) for demonstrating allogeneic islet

product comparability?

Please discuss appropriate analytical assays, bioassays, preclinical studies,

and clinical studies that may be required.

EBCR

SummarySummary

• For licensure, a well-controlled, validated manufacturing process is needed to assure the safety, purity and potency of the final product

• This requires:– Control of all starting materials used– Control and consistency of the manufacturing

process– Testing of the final product to verify it meets

predefined product safety and quality standards

Documents

Processing and Product Quality Issues Keith Wonnacott Ph.D. Office of Cellular, Tissue, and Gene Therapies E BC R Moving from Investigational to Licensed